All stock lists
Unlock the score
NewAmsterdam Pharma Co N.V. (NASDAQ:NAMS)
NL · Delayed Price · Currency is USD
Healthcare · Biotechnology
19.75+0.04 (+0.21%)
Market cap
$2.31B
Insider Score
Analyst consensus
Listed since
Feb 9, 2021
Website
Insider Score
/ 100
NAMS Insider Score
NewAmsterdam Pharma Co N.V. has a live Insider Score.
Scored on 1 qualifying trade from 1 insider in the last 90 days.
NAMS analyst forecast
NAMS analyst consensus
Moderate Buy2 ratings
Buy 2 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
NAMS 12-month price target
No published price targets in the last 12 months.
Best analysts covering NAMS
- Needham100%success rate · 8 calls
- HC Wainwright & Co.100%success rate · 1 call
- RBC Capital86%success rate · 7 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
NAMS analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-10-05 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-09-08 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-08-06 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-06-30 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-02-19 |
| — | Needham | Buy | — | — | Reiterated | 2026-02-18 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-01-21 |
| — | Stifel | Buy | — | — | Reiterated | 2025-12-16 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2025-12-02 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-11-06 |
| — | Needham | Buy | — | — | Reiterated | 2025-11-05 |
| — | Citigroup | Buy | — | — | Reiterated | 2025-10-17 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-08-07 |
| — | Needham | Buy | — | — | Reiterated | 2025-06-12 |
| — | Needham | Buy | — | — | Reiterated | 2025-05-08 |
| — | Needham | Buy | — | — | Reiterated | 2025-04-08 |
| — | Scotiabank | Sector Outperform | — | — | Reiterated | 2025-02-27 |
| — | Needham | Buy | — | — | Reiterated | 2025-02-27 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-01-28 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-01-24 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-01-14 |
| — | Scotiabank | Sector Outperform | — | — | Reiterated | 2024-12-11 |
| — | Needham | Buy | — | — | Reiterated | 2024-12-05 |
| — | Needham | Buy | — | — | Reiterated | 2024-11-21 |
| — | Needham | Buy | — | — | Reiterated | 2024-11-11 |
| — | Needham | Buy | — | — | Reiterated | 2024-11-07 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2024-09-23 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2024-09-05 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2024-07-30 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2024-06-07 |
| — | Scotiabank | Sector Outperform | — | — | Reiterated | 2024-03-14 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2024-02-29 |
| — | Credit Suisse | Outperform | — | — | Reiterated | 2023-04-03 |
NAMS earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-18 | -0.43 | -0.63 | $2.9M | $32K |
| 2026-05-07 | -0.46 | -0.40 | $1.7M | $3.0M |
| 2026-08-05 | -0.48 | -0.52 | $1.9M | $3.7M |
| 2026-11-04 | -0.49 | 0.00 | $7.5M | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.